Zoclast 4 mg/5 ml (IV Infusion)

Title

• Zoclast

Categories

• Medicine
• Bisphosphonate preparations

Description

• Zoclast is indicated in Hypercalcaemia of malignancy, Bone metastases associated with solid tumours, Osteolytic lesions associated with multiple myeloma, Corticosteroid-induced osteoporosis, Increase bone mass in men with osteoporosis, Osteoporosis in postmenopausal women, Paget's disease of bone, Prophylaxis of postmenopausal osteoporosis.
• Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone.
• The recommended dose of Zoledronic Acid in patients with multiple myeloma and metastatic bone lesions from solid tumors is 4 mg infused every 3-4 weeks.

Dosage

• The maximum recommended dose of Zoledronic Acid in hypercalcemia of malignancy (serum calcium 12 mg/dl or 3.0 mmol/l) is 4 mg.
• The recommended dose of Zoledronic Acid in patients with multiple myeloma and metastatic bone lesions from solid tumors is 4 mg infused every 3-4 weeks.

Administration

• The required amount of concentrate from one vial must be further diluted with 100 ml of calcium-free infusion solution.
• The duration of infusion must not be less than 15 minutes.
• Zoledronic Acid must not be mixed with calcium or other divalent cation-containing infusion solutions.

Interaction

• Zoclast has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without interactions.
• Caution is advised when Zoclast are administered with aminoglycosides.
• Concomitant use of loop diuretics with Zoclast increases the risk of hypocalcemia.

Contraindications

• Zoclast is contraindicated if patients have hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates.
• Severe renal impairment (Creatinine clearance <30 ml/min)
• Pregnancy and lactation

Side Effects

• Headache
• Nausea
• Anorexia
• Fatigue
• Osteonecrosis of jaw
• Anemia
• Bone pain
• Constipation
• Fever
• Vomiting
• Flu-like syndrome
• Hypocalcemia
• Myalgia
• Arthralgia
• Hypophosphataemia

Pregnancy & Lactation

• Zoledronic acid is contraindicated during pregnancy and in breast-feeding women.
• Not recommended for use in children and adolescents below 18 years of age.

Precautions & Warnings

• Patients must be appropriately hydrated prior to administration of Zoclast.
• Serum levels of calcium, phosphate, magnesium and potassium, as well as serum creatinine should be carefully monitored after initiating Zoclast therapy.

Use in Special Populations

• The use of Zoclast is not recommended in patients with severe renal impairment (Creatinine clearance <30 ml/min).
• No dose adjustment is necessary in patients with creatinine clearance >60 ml/min.

Overdose Effects

• Overdosage may cause hypocalcemia, hypophosphatemia, and hypomagnesemia.

Therapeutic Class

• Bisphosphonate preparations

Reconstitution

• Dilute the required amount in 100 mL of NaCl 0.9% or dextrose 5%.

Storage Conditions

• Store below 30° C prior to opening.
• Protect from moisture and light.
• Zoclast must be kept out of the reach and sight of children.

Related Brands

• Drometa 4 mg/5 ml (IV Infusion) - incepta-pharmaceuticals-ltd
• Zometa 4 mg/5 ml (IV Infusion) - novartis-bangladesh-ltd
• Ostometa 4 mg/5 ml (IV Infusion) - techno-drugs-ltd
• Xoleron 4 mg/5 ml (IV Infusion) - beacon-pharmaceuticals-plc
• Zerlinda 4 mg/5 ml (IV Infusion) - bots-pvt-limited